Medical technology company Teleflex (NYSE: TFX) met Wall Street’s revenue expectations in Q3 2026, with sales up 1.8% year on year to $567.8 million. Its non-GAAP profit of $2.63 per share was 39.1% above analysts’ consensus estimates.

Is now the time to buy TFX? Find out in our full research report (it’s free for active Edge members).

StockStory’s take

Teleflex’s third quarter performance was met with a positive market reaction, as the company’s non-GAAP earnings significantly surpassed analyst expectations despite revenue coming in as anticipated. Management credited progress in its transformation program, including the integration of recently acquired businesses and execution on cost initiatives, as key drivers. CEO Jason Weidman highlighted that growth in the Vascular and Surgical segments, along with early signs of recovery in Interventional, underpinned results. He emphasized actions to streamline operations and reduce complexity, which led to margin improvement and improved profitability.

Looking forward, Teleflex’s updated guidance reflects management’s expectation that transformation progress and ongoing cost discipline will support further earnings growth. The company is directing increased R&D investment toward substantive innovation, with initiatives like Freesolve and EZPLAZ positioned as long-term growth drivers. Management aims to complete major divestitures and fully implement a new global business unit structure, which CEO Jason Weidman described as critical to “building a more focused, agile, and growth-oriented Teleflex.” The team expects these efforts, along with continued capital return and debt reduction, to drive margin expansion and sustainable growth in subsequent years.

Key insights from management’s remarks

Management attributed the quarter’s results to operational transformation, portfolio integration, and focused investment in high-potential innovations.

• Segment performance diverges: Vascular and Surgical segments continued to deliver solid growth, led by intraosseous, hemostatic, and peripheral access products, while Interventional showed early improvement after prior disruption from integration and restructuring activities.
• Interventional integration progress: The company made significant strides in transitioning customers and distributors onto Teleflex platforms, resolving 90% of order-to-cash issues and reducing sales force vacancies by over 60%. Management believes this business is now positioned for ongoing recovery.
• Leadership refresh: Teleflex appointed Jason Fontana as President and General Manager of Interventional, bringing extensive experience to accelerate integration and growth. The company also added Sean Salmon to its board, strengthening cardiovascular domain expertise.
• Major divestiture advances: The Acute Care and Interventional Urology divestiture progressed through regulatory review, with management expressing confidence in completion and clarity on stranded costs and future margin implications.
• R&D investment shift: R&D spending increased from approximately 5-6% to nearly 8% of revenue, with a greater focus on developing new products such as the Freesolve resorbable scaffold and EZPLAZ freeze-dried plasma, both described as substantial long-term opportunities.

Drivers of future performance

Teleflex’s outlook centers on executing its transformation, scaling innovation, and completing divestitures to unlock operating leverage and margin gains.

• Completion of transformation initiatives: Management prioritizes finishing the Interventional business integration and closing the Acute Care and Urology divestiture, which are expected to reduce stranded costs, lower interest expense, and enable further share repurchases, supporting higher adjusted margins and earnings.
• Commercialization of new products: The company expects the Freesolve resorbable scaffold and EZPLAZ freeze-dried plasma to become meaningful contributors over time, with EZPLAZ initially targeting military and government customers before broader market expansion. Management cautioned that revenue from these innovations will build gradually as production and market adoption ramp.
• Cost discipline and global structure: Teleflex is implementing a new global business unit structure to streamline decision-making and improve customer focus. Management is also executing a multi-year restructuring plan targeting $50 million in annual pre-tax cost savings, which, combined with operating leverage from revenue growth, is projected to drive long-term profitability.

Catalysts in upcoming quarters

In future quarters, the StockStory team will monitor (1) completion of the Acute Care and Interventional Urology divestiture and associated stranded cost reductions, (2) progress in scaling production and early adoption of new products like EZPLAZ and Freesolve, and (3) evidence of sustained margin expansion as Teleflex implements its new global business unit structure. Updates on integration milestones and regulatory approvals will also be key indicators of execution.

Teleflex currently trades at $152.06, up from $150.04 just before the earnings. At this price, is it a buy or sell? Find out in our full research report (it’s free).

Now could be the perfect time to invest in these stocks

ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren’t just high-quality businesses. Something is happening with them right now. Elite fundamentals meet near-term momentum — both boxes checked at the same time.

Find out which stocks our AI platform is flagging this week. See this week’s Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+214% between June 2020 and June 2025). Find your next big winner with StockStory today.